Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 14/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 0.63 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4-Benzyloxyaniline SCHEMBL7097006 | 0.93 | AR (0.86) | ARNPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL7262553 | 0.84 | AR (0.72) | ARNPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL7094939 | 0.83 | AR (0.71) | ARNPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL27183288 | 0.83 | AR (0.70) | ARNPC1RAB9ASMN1; SMN2HPGD | |
| Benzylphenylether SCHEMBL8999674 | 0.81 | AR (0.69) | ARNPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL8050414 | 0.81 | AR (0.68) | ARNPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL25369414 | 0.79 | NR1H4 (0.69) | ARNPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL2004893 | 0.78 | AR (0.64) | ARNPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL11266317 | 0.78 | CA12 (0.70) | ARNPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL6087429 | 0.78 | AR (0.70) | ARNPC1RAB9ASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9274419-B2 | Blue photosensitive resin composition for color filter and application thereof | CHI MEI CORPORATION (TW) | 2016-03-01 | — | — | US | disclosed |
| US-9274419-B2 | Blue photosensitive resin composition for color filter and application thereof | CHI MEI CORPORATION (TW) | 2016-03-01 | — | — | US | disclosed |
| US-20150268554-A1 | BLUE PHOTOSENSITIVE RESIN COMPOSITION FOR COLOR FILTER AND APPLICATION THEREOF | CHI MEI CORPORATION (TW) | 2015-09-24 | — | — | US | disclosed |
| US-20150268554-A1 | BLUE PHOTOSENSITIVE RESIN COMPOSITION FOR COLOR FILTER AND APPLICATION THEREOF | CHI MEI CORPORATION (TW) | 2015-09-24 | — | — | US | disclosed |
| US-6605618-B2 | Antidiabetic agents; hypoglycemic agents; anticholesterol agents; side effect reduction | WYETH | 2003-08-12 | — | — | US | disclosed |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | WYETH (US) | 2003-01-23 | — | — | US | disclosed |
| US-6451814-B1 | SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION | WYETH | 2002-09-17 | — | — | US | disclosed |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | disclosed |
| WO-1998037056-A1 | PHENOXYPROPANOLAMINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM PLC (GB) | 1998-08-27 | — | — | WO | disclosed |
| US-5484780-A | CARDIOVASCULAR, HYPOTENSIVE | ELI LILLY AND COMPANY (US) | 1996-01-16 | — | — | US | disclosed |
| US-5401851-A | Preparation of proline derivatives | ELI LILLY AND COMPANY (US) | 1995-03-28 | — | — | US | disclosed |
| EP-0573271-A1 | Angiotensin II antagonists | ELI LILLY AND COMPANY (US) | 1993-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | AR 471/4885NPC1 1172/4885RAB9A 1800/4885 |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | AR 438/4885NPC1 985/4885RAB9A 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.